非选择性血液吸附通过血液净化在大鼠创伤性脑损伤和失血性休克模型中预防死亡
该研究在大鼠创伤性脑损伤(TBI)合并失血性休克(HS)模型中,比较非选择性血液吸附(HA)与假治疗对生存率的影响。雄性Sprague Dawley大鼠接受控制性皮质撞击和压力控制性失血性休克后,接入体外血液回路,实验组滤器填充可去除5 kDa至60 kDa循环分子的专有吸附珠(Cytosorbents),假手术组回路相同但不进行血液净化。主要终点为伤后96小时生存率,HA组从假手术组的47%提高至86%。HA在治疗期间及伤后4天内影响生物标志物浓度,幸存者与未幸存者生物标志物模式不同,组织学表现无治疗相关改变。
要点
- 在TBI合并HS大鼠模型中,非选择性血液吸附组96小时生存率为86%,假治疗组为47%。
- 血液吸附使用填充可去除5 kDa至60 kDa循环分子的专有吸附珠(Cytosorbents, Monmouth Junction, NJ)的滤器。
- 治疗期间及伤后4天内,血液吸附影响多种免疫介导生物标志物浓度。
- 幸存者与未幸存者的大鼠生物标志物浓度模式存在差异,提示与生存和死亡相关的标志物模式。
- 未观察到治疗相关的组织学表现改变。
适用人群与场景
- 雄性Sprague Dawley大鼠,接受控制性皮质撞击致TBI合并压力控制性失血性休克。
处置流程与药物剂量
- 实验组动物体外血液回路滤器填充专有吸附珠(Cytosorbents, Monmouth Junction, NJ),可去除5 kDa至60 kDa循环分子;假手术组回路相同但不进行血液净化。
研究设计与关键结果
- 研究类型为动物实验(大鼠模型),样本量原文未报告。
- 主要终点96小时生存率:血液吸附组86%,假治疗组47%。
- 治疗期间及伤后4天内,血液吸附影响生物标志物浓度;幸存者与未幸存者生物标志物模式不同。
- 组织学表现无治疗相关改变。
证据类型、等级与局限
- 证据类型:动物实验(大鼠TBI合并HS模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,非选择性血液吸附是预防TBI合并HS大鼠模型死亡的有效干预。
- 作者指出,血液吸附已在脓毒症人类患者中安全实施,可能成为损伤后的治疗选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients who sustain traumatic brain injury (TBI) and concomitant hemorrhagic shock (HS) are at high risk of high-magnitude inflammation which can lead to poor outcomes and death. Blood purification by hemoadsorption (HA) offers an alternative intervention to reduce inflammation after injury. We tested the hypothesis that HA would reduce mortality in a rat model of TBI and HS.
METHODS: Male Sprague Dawley rats were subjected to a combined injury of a controlled cortical impact to their brain and pressure-controlled HS. Animals were subsequently instrumented with an extracorporeal blood circuit that passed through a cartridge for sham or experimental treatment. In experimental animals, the treatment cartridge was filled with proprietary beads (Cytosorbents, Monmouth Junction, NJ) that removed circulating molecules between 5 kDa and 60 kDa. Sham rats had equivalent circulation but no blood purification. Serial blood samples were analyzed with multiplex technology to quantify changes in a trauma-relevant panel of immunologic mediators. The primary outcome was survival to 96 hours postinjury.
RESULTS: Hemoadsorption improved survival from 47% in sham-treated rats to 86% in HA-treated rats. There were no treatment-related changes in histologic appearance. Hemoadsorption affected biomarker concentrations both during the treatment and over the ensuing 4 days after injury. Distinct changes in biomarker concentrations were also measured in survivor and nonsurvivor rats from the entire cohort of rats indicating biomarker patterns associated with survival and death after injury.
CONCLUSION: Blood purification by nonselective HA is an effective intervention to prevent death in a combined TBI/HS rat model. Hemoadsorption changed circulating concentrations of multiple inmmunologically active mediators during the treatment time frame and after treatment. Hemoadsorption has been safely implemented in human patients with sepsis and may be a treatment option after injury.
参考来源
- McKinley TO, Lei Z, Kalbas Y, et al. Blood purification by nonselective hemoadsorption prevents death after traumatic brain injury and hemorrhagic shock in rats. J Trauma Acute Care Surg. 2018. PMID: 30211852. doi:10.1097/TA.0000000000002069
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。